RFK Jr outlines expansive vision for collecting US health data at Maha event - The Guardian
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
Robert F Kennedy Jr laid out an expansive vision for collecting, sharing and analyzing US health information at a Maha event hosted by a close ally and outspoken anti-vaccine activist. Medical and lifestyle data, from doctor’s visits to exercise, should be connected and shared with the government and independent researchers, where it can be searched by AI – including potential links between vaccines and health outcomes including autism and mortality, suggested Kennedy, the secretary of the US Department of Health and Human Services (HHS) and a longtime vaccine skeptic. “We need to use America’s health data to determine whether the food we eat, the chemicals we encounter, the vaccines that we’re administering, the other environmental and lifestyle exposures are contributing in one way or another to the chronic disease epidemic,” Kennedy said at an event with the Maha Institute on Monday, with about two dozen people tuning into the live stream. The Maha Institute is headed by Mark Gorton, who called himself “the boldest anti-vaxxer in the anti-vax conference” two weeks ago.
This article is an excerpt. To read the full content, visit the original source. The Guardian
Related articles
MAHA Gone Mild - The Atlantic
Public Health Needs MAHA - The Atlantic
XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout - The Globe and Mail
● Clinical Trial Application planned for filing with Health Canada, extending the Company’s international regulatory strategy for gout program XRx-026 ●CALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide an outline of its anticipated Clinical Trial Application (“CTA”) submission to Health Canada for the XRx-026 gout program. The filing supports the Company’s planned two-part clinical study, XRX-OXY-102, evaluating XORLOTM, the Company’s proprietary formulation of oxypurinol, a xanthine oxidase inhibitor, for the treatment of gout. Conducting the first part of the XRX-OXY-102 clinical study in Canada is expected to enable the Company to accelerate the delivery of key clinical data in support of its planned New Drug Application (“NDA”) filing with the U. S. Food and Drug Administration (the “FDA”) for marketing approval. Recent drug development team activities have included parallel preparation of the CTA for filing with Health Canada.
0 comments
No comments yet. Be the first to share your thoughts!